Patheon, a global provider of drug development and manufacturing services to the international pharmaceutical industry, has signed a technology transfer agreement with Dendreon Corporation for commercial supply of proprietary density gradient solutions required during the PROVENGE(R) (sipuleucel-T) manufacturing process. PROVENGE was approved by the U.S. Food and Drug Administration (FDA) on April 29, 2010 for the treatment of asymptomatic or minimally symptomatic castrate resistant (hormone refractory) prostate cancer.
“We are very excited that Dendreon has chosen Patheon to help them bring to market this promising new therapy. Our agreement is further evidence that we are being recognized in the industry as the contract development and manufacturer of choice. We have dedicated ourselves to understanding our customer’s needs and developing both the capability and capacity to deliver on those needs. We’re happy that Dendreon has trusted us to be part of the commercialization of this product,” said Wes Wheeler, Patheon’s Chief Executive Officer and President.
PROVENGE is the first autologous cellular immunotherapy to be approved by the FDA and is based on a unique technology platform.
